High-flow Oxygen and Nitric Oxide inhalation versus high-flow oxygen alone on the incidence of intubation in hypoxaemic Respiratory failure (HONOR): a pilot randomised controlled trial.

uke Churchill0 个研究点目标入组 40 人开始时间: 2022年11月4日最近更新: 2022年11月14日

适应症

试验速览

暂无简介。

•Age greater than or equal to 18 years, meeting the following criteria
•oDe novo type I respiratory failure (hypoxaemia in the absence of chronic lung condition) (41)
•oPF ratio <300mmHg
•oHigh flow nasal cannula determined by ICU medical team to be primary method for delivery of oxygen therapy
•oAnticipated high-flow oxygen (HFO2) requirement >24 hours
•oArterial line in-situ for blood gas sampling
•Ability to provide informed consent, or consent via a substitute decision maker
•oWhere emergency treatment is required rapidly, and the involvement in the research carries no more risk to participants than not participating, a consent waiver may be initiated, until a time point where the patient or their substitute decision maker can give informed consent

•Underlying chronic respiratory failure or exacerbation of asthma (including COPD or another chronic respiratory disease)
•Documented cardiogenic pulmonary oedema or acute coronary syndrome
•Hypercapnic respiratory failure with PaCO2 > 45mmHg
•Deterioration of neurologic status demonstrated by Glasgow Coma Scale (GCS) less than or equal to 12
•Urgent need for intubation (evaluated by the medical officer in charge)
•Haemodynamic instability (defined by systolic arterial blood pressure <90mmHg or mean arterial blood pressure <65 mmHg)
•Use of vasopressors
•Do not intubate orders
•Enrolled in any other trial of targeted oxygen therapy

发起方

uke Churchill